58 search results for: asthma
ADVENT at ERS 2026
Join Sanofi and Regeneron for four educational symposia on asthma, COPD, and the unified airway.
Compounded Burden of Co-existing Type 2 Airway Diseases
In this video soundbite from the EAACI 2025 symposium, Dr. Brian Lipworth discusses that co-existing type 2 inflammatory diseases are common in patients with CRSwNP & increasing severity of asthma is associated with higher severity of CRS and prevalence of nasal polyps. Additionally, he explains that patient burden is substantially greater when asthma and CRSwNP are co-existing.
EAACI 2024 | On-Treatment Clinical Remission in Upper and Lower Airways: Going Beyond Symptom Control
Join experts G. Walter Canonica, Vibeke Backer, and Joaquim Mullol for an educational symposium on elevating treatment goals from control to remission in the upper and lower airways.
ERS 2024 | Airway Remodeling: A Permanent or Transitory Consequence in Severe Asthma Patients?
Join Klaus Rabe, MD, PhD, FERS; Celeste Porsberg, MD, PhD; and Mario Castro, MD, MPH, for a symposium on airway remodeling in severe asthma patients.
Mechanisms of Production and Clinical Impact of IgE
Explore how type 2 inflammation drives the production of IgE in severe asthma
Exploring the Mechanisms of FeNO Production in the Lungs
Explore how type 2 inflammation drives the production of FeNO in severe asthma
Type 2 Asthma Learning Hub
Type 2 asthma is a common phenotype of asthma, characterized by key cytokines IL-4, IL-13, and IL-5, as well as elevated type 2 inflammatory biomarkers as FeNO, and eosinophils, or the need for maintenance OCS. Type 2 inflammation is evident in up to 88% of patients with severe asthma, representing a substantial portion of the disease burden associated with asthma. Explore the resources below better understand the role of type 2 inflammation in asthma.
Clinical Manifestations Associated With Airway Remodeling in Asthma
Join Dr. Hanania to understand how to identify patients at risk of fixed airway obstruction in clinical settings.
ADVENT at ERS 2024
The ADVENT program will present four symposia sharing the latest science in asthma and COPD at the 2024 European Respiratory Society (ERS) Congress. Visit Booth #A4.02 to learn more about ADVENT.
Giselle Mosnaim, MD, MS, FAAAAI, FACAAI
Giselle Mosnaim is a board-certified allergist and immunologist at Endeavor Health and Clinical Assistant Professor at the University of Chicago Pritzker School of Medicine. An internationally recognized expert in asthma and allergic diseases, her clinical and research interests focus on severe and uncontrolled asthma, digital health, and improving patient outcomes through innovative, evidence-based care.
Celeste Porsbjerg, MD, PhD
Professor of Severe Asthma, Bispebjerg Hospital Copenhagen, Denmark
Nicole Chase, MD
Associate Professor of Medicine, University of Minnesota; Physician Minneapolis VA Health Care System; Partner, St. Paul Allergy & Asthma, PA
